Physician profile
James Brooks
NPI 1659721918
$3,997.43
in general payments reported to CMS, 2019-2025
23 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,254 · 2022: $803 · 2023: $1,100 · 2024: $514 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $774.84 | 2021-2023 | Tezspire |
| Abbvie INC. | $467.05 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $337.09 | 2021-2025 | Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $256.54 | 2022 | |
| Scpharmaceuticals INC. | $220.45 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $208.58 | 2024-2025 | |
| Amgen INC. | $166.40 | 2022-2023 | Repatha |
| Abbott Laboratories | $140.10 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $124.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Otsuka America Pharmaceutical, INC. | $121.84 | 2025 | |
| Eisai INC. | $121.45 | 2024 | |
| Edwards Lifesciences Corporation | $119.01 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $116.28 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $109.51 | 2021 | |
| Novo Nordisk INC | $106.61 | 2021 | |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Cvrx, INC. | $84.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $84.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.50 | 2021-2023 | Xarelto |
| Coloplast Corp | $27.82 | 2023 | Titan |
| Pfizer INC. | $26.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.